Table 3.
The allele frequencies of human leukocyte antigen-B (HLA-B) in the patients with Kawasaki disease and the control subjects
| HLA alleles | Healthy controls (n = 159) n (%) | KD patients (n = 74) n (%) | Coronary complications | |
|---|---|---|---|---|
| Present (n = 21) n (%) | Absent (n = 53) n (%) | |||
| HLA-B | ||||
| 07 | 19 (11.9) | 9 (12.2) | 3 (14.3) | 6 (11.3) |
| 08 | 2 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 13 | 20 (12.6) | 5 (6.8) | 2 (9.5) | 3 (5.7) |
| 14 | 6 (3.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 27 | 11 (6.9) | 3 (4.1) | 1 (4.8) | 2 (3.8) |
| 35 | 11 (6.9) | 14 (18.9)a | 4 (19.0) | 10 (18.9)b |
| 37 | 5 (3.1) | 4 (5.4) | 2 (9.5) | 2 (3.8) |
| 38 | 7 (4.4) | 3 (4.1) | 0 (0.0) | 3 (5.7) |
| 39 | 2 (1.3) | 3 (4.1) | 2 (9.5) | 1 (1.9) |
| 44 | 29 (18.2) | 10 (13.5) | 3 (14.3) | 7 (13.2) |
| 46 | 18 (11.3) | 7 (9.5) | 2 (9.5) | 5 (9.4) |
| 47 | 0 (0.0) | 1 (1.4) | 0 (0.0) | 1 (1.9) |
| 48 | 13 (8.2) | 2 (2.7) | 0 (0.0) | 2 (3.8) |
| 51 | 29 (18.2) | 13 (17.6) | 5 (23.8) | 8 (15.1) |
| 52 | 9 (5.7) | 3 (4.1) | 2 (9.5) | 1 (1.9) |
| 54 | 23 (14.5) | 10 (13.5) | 3 (14.3) | 7 (13.2) |
| 55 | 3 (1.9) | 4 (5.4) | 1 (4.8) | 3 (5.7) |
| 56 | 2 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 57 | 2 (1.3) | 1 (1.4) | 0 (0.0) | 1 (1.9) |
| 58 | 15 (9.4) | 5 (6.8) | 0 (0.0) | 5 (9.4) |
| 59 | 4 (2.5) | 3 (4.1) | 0 (0.0) | 3 (5.7) |
| 60 | 11 (6.9) | 7 (9.5) | 2 (9.5) | 5 (9.4) |
| 61 | 23 (14.5) | 13 (17.6) | 6 (28.6) | 7 (13.2) |
| 62 | 29 (18.2) | 14 (18.9) | 1 (4.8) | 13 (24.5) |
| 67 | 4 (2.5) | 2 (2.7) | 1 (4.8) | 1 (1.9) |
| 71 | 7 (4.4) | 1 (1.4) | 0 (0.0) | 1 (1.9) |
| 75 | 2 (1.3) | 7 (9.5)c | 0 (0.0) | 7 (13.2)d |
KD, Kawasaki disease; RR, relative risk
ap < 0.006; RR = 3.1 (95% confidence interval [CI], 1.29–7.62) vs healthy control subjects
bp < 0.02; RR = 3.1 (95% CI, 1.16–8.43) vs healthy control subjects
cp < 0.02; RR = 8.2 (95% CI, 1.74–38.68) vs healthy control subjects
dp < 0.003; RR = 11 (95% CI, 2.79–51.13) vs healthy control subjects